https://kanker-actueel. nl/arseentrioxide-ato-plus-all-trans-retinoinezuur-atra-en-ascorbinezuur-vitamine-c-als-onderhoudsbehandeling-na-de-eerste-volledige-remissie-bij-acute-promyelocytische-leukemie-apl-geeft-uitstekende-overall-overleving-op-5-en-10-jaar. html

作者: A Ghavamzadeh , K Alimoghaddam , SH Ghaffari , S Rostami , M Jahani

DOI:

关键词:

摘要: RESULTS: Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1-57) months, 1-and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1-and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically.CONCLUSIONS: Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.

参考文章(0)